Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
CPRX

CPRX - Catalyst Pharmaceuticals Inc Stock Price, Fair Value and News

$23.21-0.18 (-0.77%)
Market Closed

86/100

CPRX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

86/100

CPRX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

CPRX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CPRX Price Action

Last 7 days

-4.2%

Last 30 days

-3.0%

Last 90 days

-1.7%

Trailing 12 Months

11.2%

CPRX RSI Chart

CPRX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CPRX Valuation

Market Cap

2.8B

Price/Earnings (Trailing)

13.23

Price/Sales (Trailing)

4.81

EV/EBITDA

7.47

Price/Free Cashflow

13.59

CPRX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

CPRX Fundamentals

CPRX Revenue

Revenue (TTM)

589.0M

Rev. Growth (Yr)

7.61%

Rev. Growth (Qtr)

2.84%

CPRX Earnings

Earnings (TTM)

214.3M

Earnings Growth (Yr)

-5.79%

Earnings Growth (Qtr)

-0.16%

CPRX Profitability

EBT Margin

48.14%

Return on Equity

22.46%

Return on Assets

19.41%

Free Cashflow Yield

7.36%

CPRX Investor Care

Shares Dilution (1Y)

0.56%

Diluted EPS (TTM)

1.69

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025534.6M558.5M578.2M589.0M
2024411.3M434.5M460.5M491.7M
2023256.5M302.9M348.4M398.2M
2022153.7M170.5M191.8M214.2M
2021120.1M126.9M133.5M140.8M
2020119.0M119.8M118.2M119.1M
201936.6M54.6M72.7M102.3M
201800018.5M
2010000489.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About Catalyst Pharmaceuticals Inc

CPRX
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
 CEO
 WEBSITEcatalystpharma.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES82

Catalyst Pharmaceuticals Inc Frequently Asked Questions

CPRX is the stock ticker symbol of Catalyst Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Mar 13 2026, market cap of Catalyst Pharmaceuticals Inc is 2.83 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Mar 13 2026, CPRX's PE ratio (Price to Earnings) is 13.23 and Price to Sales (PS) ratio is 4.81. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CPRX PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Catalyst Pharmaceuticals Inc has provided 0.354 (multiply by 100 for percentage) rate of return.